Next-generation biotech Ginkgo Bioworks Holdings (NYSE: DNA) was one of the star stocks in its sector this week. According to data compiled by S&P Global Market Intelligence, the company’s share price raced nearly 34% higher over the five market sessions. Two newly announced partnerships were a key reason, particularly the one involving artificial intelligence (AI).
It’s not only the fact that the one tie-up covers AI; it’s also the company Ginkgo is teaming with. On Tuesday, the biotech announced that it has begun a strategic cloud and AI partnership with Alphabet‘s Google Cloud unit.
The term of the Ginkgo/Alphabet deal is five years, under which Ginkgo will develop large language models running on its partner’s Vertex AI platform. Google Cloud, meanwhile, is to be its primary provider of cloud computing services.
In the press release trumpeting the arrangement, Ginkgo quoted CEO Jason Kelly as saying, “With Ginkgo’s automated Foundry to generate large scale biological data, Google Cloud’s computing horsepower, and Google’s AI expertise, I can’t think of a better partner to scale AI solutions in biological engineering.”
AI is a white-hot area of investor interest right now, and any company that indicates deeper involvement in the technology is sure to win the right kind of attention from the market.
Compounding that for Ginkgo, on Thursday it announced another promising partnership. Privately held Exacta Bioscience is using Ginkgo’s agricultural research and development services for one of its projects.
This is described by the latter company as “a fermentation optimization and scale-up program to enhance one of its crop protection products, FitoRoot, paving the way for large-scale commercialization.”
Ginkgo did not provide the financial particulars of either deal in its press releases.
10 stocks we like better than Ginkgo Bioworks
When our analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*
They just revealed what they believe are the ten best stocks for investors to buy right now… and Ginkgo Bioworks wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
*Stock Advisor returns as of August 28, 2023
Suzanne Frey, an executive at Alphabet, is a member of The Motley Fool’s board of directors. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet. The Motley Fool has a disclosure policy.
Blog powered by G6
Disclaimer! A guest author has made this post. G6 has not checked the post. its content and attachments and under no circumstances will G6 be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your use of or inability to use this website or any websites linked to it, or from your reliance on the information and material on this website, even if the G6 has been advised of the possibility of such damages in advance.
For any inquiries, please contact [email protected]